Wesley A. Mayer, MD, presented “The Bottom Line: Practical Application of Clinical Trial Data to Advanced Renal Cell Carcinoma” during the 23rd Annual Innovations in Urologic Practice on September 14, 2018 in Santa Fe, New Mexico.
How to cite: Mayer, Wesley A.. “The Bottom Line: Practical Application of Clinical Trial Data to Advanced Renal Cell Carcinoma?” September 14, 2018. Accessed Nov 2024. https://dev.grandroundsinurology.com/the-bottom-line-practical-application-of-clinical-trial-data-to-advanced-renal-cell-carcinoma/
The Bottom Line: Practical Application of Clinical Trial Data to Advanced Renal Cell Carcinoma – Summary:
Wesley A. Mayer, MD, reviews the landmark trials that set the standard of care for cytoreductive nephrectomy (CN) and the impact of targeted therapy on this technique. He discusses recent clinical trials on CN and targeted therapy, as well as data regarding cytoreductive partial nephrectomy.
Abstract:
Although the 5-year survival rate for localized kidney cancer is 93%, it is dismal for metastatic disease. Two landmark randomized prospective multicenter trials, a SWOG study and an EORTC study, demonstrated level 1 evidence for a survival benefit over interferon alone in 2001. This generated the adoption of CN into common practice.
However, the discovery of some of the mechanisms behind the molecular basis of kidney cancer resulted in a prolific growth of drug development.
Ultimately, this led to approval of 11 novel agents for targeted treatment of metastatic kidney cancer between 2005 and 2018. This resulted in significant changes in the utilization of cytoreductive nephrectomy. Until recently, only retrospective data was available concerning the outcomes of cytoreductive nephrectomy in this new era of targeted therapy.
This presentation reviews 2 recent randomized multicenter prospective surgical trials and how their outcomes might impact the treatment of metastatic kidney in the future. The conversation also briefly covers feasibility and outcomes of cytoreductive partial nephrectomy.
About Innovations in Urologic Practice
Innovations in Urologic Practice (IUP) is an annual CME-accredited conference devoted to updating urologists on the rapidly changing healthcare environment. Topics focus on innovative diagnostic and treatment strategies, controversies, new and currently developing technologies, and challenges in today’s urologic practice. Dr. Mayer presented this lecture during the 23rd IUP in 2018. Please visit this page in order to learn more about future IUP meetings.
ABOUT THE AUTHOR
Dr. Mayer is an Associate Professor of Medicine at Baylor College of Medicine in Houston, Texas. He specializes in advanced minimally invasive surgical treatments for urologic diseases, including robotic, laparoscopic (including single-site), endourologic, and percutaneous surgery. He has a special interest in kidney cancer, kidney stones, upper urinary tract reconstruction, adrenal masses, and transplant urology. Dr. Mayer graduated from Baylor College of Medicine with the highest honors. He completed his internship in general surgery and his urology residency at the University of Pennsylvania. He was fellowship-trained in minimally invasive urology by Baylor College of Medicine’s Scott Department of Urology.
Dr. Mayer has published research on robotic partial nephrectomy, single-site donor nephrectomy, and treatment of kidney stones. Dr. Mayer is currently Baylor College of Medicine’s Urology Residency Program Director, and education is a major focus of his. His education initiatives have been presented at national meetings. Dr. Mayer has been recognized for his outstanding teaching and education efforts with the prestigious Norton Rose Fulbright Faculty Excellence Award for Teaching and Evaluation as well as the Norton Rose Fulbright Faculty Excellence Award for Educational Leadership. He has also been selected as a “Top Urologist in Houston, TX” by The Leading Physicians of the World, as well as a “Top Doctor 2019” by Houstonia Magazine.
